Open randomized study for the evaluation of activities of AS/AQ (co-packaged and co-formulated) versus AL on asexual & sexual paraistes in children

Conditions

Malaria Paediatrics

Akintunde Sowunmi, Godwin Ntadom, Kazeem Akano, Folasade O. Ibironke, Adejumoke Idowu Ayede et al. (36 authors)

Infectious Diseases of Poverty2019-08-0619 citations

Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments.

Sowunmi A, Akano K, Ntadom G, Ayede AI, Ibironke FO, Aderoyeje T, Adewoye EO, Fatunmbi B, Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, Agomo C, Folarin OA, Gbotosho GO, Happi CT.

2017-02-0712 citations

10.1186/s40249-016-0217-7

Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria

Akintunde Sowunmi, Kazeem Akano, Adejumoke Idowu Ayede, Elsie O. Adewoye, Godwin Ntadom et al. (9 authors)

BMC Infectious Diseases2017-01-317 citations

10.1186/s12879-016-2173-z

Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Adewoye EO, Fatunmbi B, Aderoyeje T.

2016-07-065 citations

10.1186/s40249-016-0165-2

Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Aderoyeje T, Adewoye EO, Fatunmbi B.

2016-06-0111 citations

10.1186/s12879-016-1565-4

Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.

Sowunmi A, Akano K, Ayede AI, Ntadom G, Fatunmbi B, Aderoyeje T, Adewoye EO.

2015-10-2610 citations

10.1186/s12879-015-1219-y

Interventions

amodiaquine plus artesunate

artemisinin plus amodiaquine (co-formulated)

artemether plus lumefantrine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: boby weight at least 5 kg History of fever microscopically confirmed pure Plasmodium falciparum infection >/= 2000/uL Presence or history of fever (temp. >37.4) written informed consent

Exclusion criteria

Exclusion criteria: severe malaria History of alergy to study drugs Presence of concomitant illness Signs of severe malnutrition Patient with history of hepatic, cardiac or renal disease.

Design outcomes

Primary

Measure	Time frame
28-42 days PCR-corrected cure rates	—

Secondary

Measure	Time frame
Proportion of patients with parasitaemia or fever;Prevalence and intesities of gametocytaemia	—

Countries

Nigeria

Contacts

Public ContactAkintunde Sowunmi

Professor

akinsowunmi@hotmail.com08052157893

Outcome results

None listed